Furthermore, while ICIs have transformed NSCLC treatment, their role in EGFR‐mutant NSCLC post‐TKI resistance is controversial, with conflicting data on the impact of PD‐L1 expression and T790M status [13]. Here, CD274 is linked to non-small cell lung carcinoma.